ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s share price shot up 9.1% during mid-day trading on Thursday . The company traded as high as $2.22 and last traded at $2.16. 1,999,995 shares changed hands during mid-day trading, an increase of 43% from the average session volume of 1,395,745 shares. The stock had previously closed at $1.98.
The company has a market capitalization of $277.64 million, a PE ratio of -4.08 and a beta of 1.26.
ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.12). As a group, analysts expect that ZIOPHARM Oncology Inc. will post -0.5 earnings per share for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the company. UBS Group AG boosted its stake in shares of ZIOPHARM Oncology by 35.3% in the 1st quarter. UBS Group AG now owns 872,376 shares of the biotechnology company’s stock worth $3,420,000 after buying an additional 227,812 shares during the last quarter. BlackRock Inc. boosted its stake in shares of ZIOPHARM Oncology by 8.5% in the 2nd quarter. BlackRock Inc. now owns 9,167,740 shares of the biotechnology company’s stock worth $27,686,000 after buying an additional 717,804 shares during the last quarter. First Hawaiian Bank purchased a new position in shares of ZIOPHARM Oncology in the 3rd quarter worth $333,000. Russell Investments Group Ltd. purchased a new position in shares of ZIOPHARM Oncology in the 1st quarter worth $911,000. Finally, MetLife Investment Advisors LLC boosted its stake in shares of ZIOPHARM Oncology by 77.1% in the 2nd quarter. MetLife Investment Advisors LLC now owns 65,990 shares of the biotechnology company’s stock worth $199,000 after buying an additional 28,734 shares during the last quarter. Hedge funds and other institutional investors own 39.39% of the company’s stock.
ZIOPHARM Oncology Company Profile (NASDAQ:ZIOP)
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.
Further Reading: What are trading strategies for the 52-week high/low?
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.